ocular therapeutix inc ocular therapeutix inc ocular therapeutix is a biopharmaceutical company dedicated to the discovery development manufacturing and commercialization of innovative drug products focused on the treatment of ocular diseases and conditions new slide text – ocular therapeutix feature products intracanalicular inserts extended release dexamethasone and extended release travoprost caution new drugs  extended release intracanalicular inserts are investigational new drugs undergoing clinical evaluation in the us and are not approved by the fda as safe or effective read more about intracanalicular inserts sustained release intravitreal depots evaluating small tki and large protein molecule drug depots for retinal diseases caution new drugs – sustained release intravitreal depots are investigational new drugs in preclinical development that are not approved by the fda as safe or effective read more about sustained release intravitreal depots ocular sealant resure sealant caution new drugs  extended release intracanalicular inserts are investigational new drugs undergoing clinical evaluation in the us and are not approved by the fda as safe or effective read more about the resure sealant top careers ocular therapeutix inc ocular therapeutix inc  company  careerscareers ocular therapeutix is a fast growing innovative ophthalmic biopharmaceutical company that is transforming the industry by developing and commercializing firstofakind therapies to drive our continued success we’re looking for selfstarting ambitious goaloriented and talented professionals who want to be part of a fastmoving entrepreneurial environment employee benefits in addition to a comprehensive compensation package ocular therapeutix offers a business casual environment and exceptional employee benefits including medical insurance dental insurance k retirement plan shortterm and longterm disability insurance life insurance accidental death insurance discounted stock options paid vacation and paid holidays the benefits highlighted above provide a basic outline of the company benefits offered to our employees summary plan documents of the current benefit plans will be provided upon employment and are subject to change if you would like to become a member of our highimpact team please view our job openings below to apply clinical data specialist ii june  the clinical data specialist will be responsible for ongoing data review cleaning and discrepancy management on one or two studies at a time  assist with study startup activities such as crf design crf completion guidelines edit check specifications and database testing clinical project manager february  the clinical project manager is responsible for managing clinical trials from initiation to completion through leading the development of study protocols case report forms and clinical reports as well as overseeing site monitoring visits and interfacing with site staff clinical research organizations cro and other company representatives this position is also responsible for supporting clinical trials as required cra ii february  this is an exciting opportunity for an energetic and organized cra with at least  years monitoring experience to grow their clinical career to a cra ii in this position you will assist and provide support to the members of the clinical trial team in order to facilitate the clinical trial processes including execution of clinical trials the cra ii will assist with the following designing implementing and maintaining clinical trials writing protocols case report forms and consent forms and recruiting and selecting investigators and ensuring good clinical practices are followed director quality control march  the director quality control directs the development planning implementation and maintenance of quality methods processes and operations for new or existing products andor technologies the qc group is comprised of the following functions analytical chemistry microbiology environmental monitoring qc inspection and support this individual will provide strategic and tactical leadership to the quality organization ensuring the execution of responsibilities within the quality systemthis position manages people and is responsible for all work completed within the qc group for pharmaceutical and medical device products medical science liaison may  we are seeking medical science liaisons with preferably  years’ experience but minimally  year msl experience to cover the southeastern portion of the us or the western pennsylvania region the medical science liaison msl plays an integral role in medical affairs at ocular therapeutix being part of a small strategic team of medical science experts who interact with regional and national key opinion leaders kols and local customers this individual will have significant responsibility and is expected to provide indepth scientific clinical and educational support to external customers in addition to internal clinical sales and marketing teams the msl also provides scientific insight back to medical affairs management regulatory affairs project manager march  the regulatory affairs project manager will work with regulatory management and project team members to identify and execute regulatory strategies to obtain commercial approval of ocular therapeutix products worldwide this individual will oversee the execution of complex project tasks relevant to regulatory affairs from product inception to product launch senior cra february  reporting to the clinical project manager the senior cra will assist and provide support to the members of the clinical trial team in order to facilitate the clinical trial processes including execution of clinical trials the senior cra is responsible for designing implementing and maintaining clinical trials and heshe will write protocols case report forms and consent forms recruit and select investigators and ensure good clinical practices are followed company hydrogel technology management team board of directors careers top pipeline ocular therapeutix inc ocular therapeutix inc  product candidatesproduct candidates product candidates dextenza™ otxtp travoprost insert intravitreal depots top contact ocular therapeutix ocular therapeutix inc ocular therapeutix inc  contact uscontact us   designator dr mr mrs ms name  first last  last title md od nppa address  city  state  al ak as az ca co ct de fl ga hi id il in ia ks ky la me md ma mi mn ms mo mt ne nv nh nj nm ny nc nd oh ok or pa ri sc sd tn tx ut vt va wa wv wi wy international zip code  email address  phone please select doctor patient other hcp other comments  receive more information yes i would like to receive informational updates regarding ocular therapeutix the resure sealant and future product information contact us locations top management team ocular therapeutix inc ocular therapeutix inc  company  management teammanagement team   amar sawhney phd president chief executive officer and chairman of the board of directors amarpreet sawhney phd has served as president chief executive officer and a member of our board since cofounding the company in  and he was elected as chairman of the board in june  dr sawhney served as ceo of augmenix an affiliate of ocular therapeutix from  until april  in addition he is a general partner of incept llc an intellectual property holding company previously dr sawhney founded confluent surgical and served as its president and ceo prior to its acquisition by covidien plc he also was a technology founder of focal inc a biopharmaceutical company acquired by genzyme corporation and a founder of accessclosure inc acquired by cardinal health in  dr sawhney’s innovations are the subject of over  issued and pending patents he holds ms and phd degrees in chemical engineering from the university of texas at austin as well as a btech in chemical engineering from the indian institute of technology delhi india jim fortune chief operating officer jim fortune has more than  years of senior operating experience in both public and private companies within the healthcare sector he joined ocular therapeutix in  also serving as chief operating officer of augmenix from  until april  and as coo of accessclosure from  to  previously mr fortune served in coo positions at intrinsic therapeutics and prior to this at confluent surgical he also had a year career in management roles of increasing responsibility within the orthopedic and neurosurgical divisions of johnson  johnson mr fortune received a bs degree in mechanical engineering from rensselaer polytechnic institute andy hurley chief commercial officer andy hurley joined ocular therapeutix in late  and brings to the company over  years of commercial leadership experience across sales marketing commercial operations and managed care functions within the pharmaceutical industry prior to joining ocular therapeutix mr hurley served as vice president sales and marketing at dyax corporation prior to dyax mr hurley was a principal at capgemini consulting a top  global management consulting firm where he was responsible for leading the sales and marketing effectiveness practice within the life sciences group before joining capgemini mr hurley held several senior level positions within sunovion pharmaceuticals including vice president of marketing and vice president of commercial operations at sunovion he was responsible for leading all marketing activities for the asthma franchise and also had the opportunity to lead  functions within the commercial operations department earlier in his career mr hurley held sales leadership and commercial operations roles at forest pharmaceuticals and nitromed mr hurley earned a bs degree in consumer studies at the university of vermont and pursued graduatelevel coursework in marketing and finance at bentley university peter jarrett phd chief scientific officer peter jarrett phd has more than  years of rd experience ranging from discovery to commercialization dr jarrett joined ocular therapeutix in  previously he was vice president of rd at focal subsequently being named vp of biomaterials rd at genzyme upon the latter company’s acquisition of focal dr jarrett began his career in corporate rd of american cyanamid later moving to the davis and geck division at cyanamid focal genzyme and ocular dr jarrett developed bioresorbable polymers for medical devices and drug delivery systems resulting in numerous patents and publications dr jarrett holds a ba degree in chemistry from connecticut college and a phd degree in polymer science from the university of connecticut institute of materials science george migausky chief financial officer – interim mr george migausky brings more than  years of experience in senior financial management to ocular therapeutix mr migausky was executive vice president and chief financial officer of dyax corp through its  billion merger with shire plc in  previously mr migausky served as the cfo of wellstat management company a firm responsible for strategy and operations of an affiliated group of five life science companies prior to this he held cfo positions at several public and private companies including igen international inc where he played a pivotal role in the company’s ipo and subsequent  billion merger with f hoffman la roche mr migausky is on the boards of dimension therapeutics inc and hyperion catalysis international and is a trustee at the massachusetts ear and eye infirmary he received his mba degree from babson college and bs degree from boston college eric ankerud jd executive vice president regulatory quality and compliance eric ankerud has more than  years of product approval experience covering a wide range of pharmaceuticals medical devices and biologics he joined ocular therapeutix in  also serving as executive vice president clinical regulatory and quality at a sister company augmenix from  until april  previously mr ankerud was the vice president clinical regulatory and quality of confluent surgical inc and prior to this held senior executive positions at boston scientific corporation summit technology inc and bausch  lomb he has also held senior management roles within cr bard and its surgical products group mr ankerud received a ba degree with highest honors in economics from st lawrence university and a jd degree from the faculty of law and jurisprudence state university of new york at buffalo scott corning vice president marketing  commercial operations scott corning has more than  years of ophthalmic medical device and pharmaceutical marketing experience covering a range of ophthalmic surgical equipment diagnostic devices and pharmaceuticals prior to joining ocular therapeutix in  mr corning held marketing management positions at alcon in both the surgical and pharmaceutical divisions and prior to that at summit technology and euroclear in brussels mr corning earned a ba degree from wesleyan university and received an msma degree in management and international relations from boston university in brussels belgium art driscoll vice president product development art has more than  years of biomaterials medical device and biotech experience in both public and private companies with a strong record of developing technologies from bench top through commercialization prior to joining ocular therapeutix in  mr driscoll was vice president of biosurgery rd for covidien’s surgical solutions business and previously held senior management positions at confluent surgical and boston scientific mr driscoll has a bs degree in industrial technology and was a candidate for an ms degree in plastics engineering from the university of lowell greg gangemi vice president sales greg gangemi has over  years of commercial leadership experience across the sales market access and commercial operations functions within the pharmaceutical healthcare and technologies industries prior to joining ocular therapeutix mr gangemi served as head of integrated delivery networks at ferring pharmaceuticals prior to ferring mr gangemi was vice president of operations at dovetail health a patient adherence provider leading all aspects of sales marketing and commercial operations prior to dovetail mr gangemi founded a sales force effectiveness software platform at blue sail inc targeted to increase sales impact within the healthcare sector he has also held several senior level positions at cubist pharmaceuticals where he served as vice president of sales and market access and at sunovion pharmaceuticals where he was vice president of sales mr gangemi earned a bs degree in economics from wagner college company hydrogel technology management team board of directors careers top about ocular therapeutix ocular therapeutix inc ocular therapeutix inc  companycompany ocular therapeutix inc nasdaq ocul is a biopharmaceutical company focused on the discovery development manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology ocular therapeutix’s lead product candidate dextenza™ dexamethasone insert mg for intracanalicular use has completed phase  clinical development for postsurgical ocular inflammation and pain dextenza is also in phase  clinical development for allergic conjunctivitis otxtp travoprost insert is in phase  clinical development for glaucoma and ocular hypertension ocular therapeutix is also evaluating injectable drug delivery depots for backoftheeye diseases the company’s first commercial product the resure® sealant is the first and only sealant that has been approved by the food and drug administration fda for ophthalmic use vision statement aspiring to be a leader in ophthalmology by leveraging its proven hydrogel platform technology to innovate elegant drug product solutions that improve outcomes in ocular diseases and enhance patient and provider experience company hydrogel technology management team board of directors careers top ocular therapeutix ocul eps estimated at  sabby management has trimmed its immunomedics immu holding  bibey post trending stock news penny stock news market news stock news ocular therapeutix ocul eps estimated at  sabby management has trimmed its immunomedics immu holding july    by marie mckinney sabby management llc decreased immunomedics inc immu stake by  reported in q sec filing sabby management llc sold  shares as immunomedics inc immu’s stock rose  the sabby management llc holds  shares with  value down from  last quarter immunomedics inc now has m valuation the stock rose  or  reaching  about  shares traded immunomedics inc nasdaqimmu has risen  since july   and is uptrending it has outperformed by  the sp analysts expect ocular therapeutix inc nasdaqocul to report  eps on august they anticipate  eps change or  from last quarter’s  eps after having  eps previously ocular therapeutix inc’s analysts see  eps growth about  shares traded ocular therapeutix inc nasdaqocul has declined  since july   and is downtrending it has underperformed by  the sp among  analysts covering ocular therapeutix nasdaqocul  have buy rating  sell and  hold therefore  are positive ocular therapeutix had  analyst reports since august   according to sratingsintel cantor fitzgerald maintained the shares of ocul in report on monday july  with “buy” rating on friday february  the stock rating was initiated by cantor fitzgerald with “overweight” morgan stanley downgraded the shares of ocul in report on friday june  to “equalweight” rating nomura initiated the shares of ocul in report on wednesday august  with “buy” rating on friday october  the stock rating was downgraded by morgan stanley to “equalweight” the rating was initiated by morgan stanley with “equal weight” on thursday august  morgan stanley upgraded it to “overweight” rating and  target in thursday february  report btig research maintained the shares of ocul in report on tuesday july  with “hold” rating jmp securities initiated the shares of ocul in report on thursday august  with “outperform” rating morgan stanley maintained it with “overweight” rating and  target in thursday april  report ocular therapeutix inc is a biopharmaceutical company the company has market cap of  million the firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology it currently has negative earnings the company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye investors sentiment increased to  in q  its up  from  in q it increased as  investors sold immu shares while  reduced holdings  funds opened positions while  raised stakes  million shares or  more from  million shares in q were reported  million are owned by state street corp  million are held by everpoint asset ltd blackrock advisors lc accumulated  or  shares j goldman co lp holds  of its portfolio in immunomedics inc nasdaqimmu for  shares tourbillon capital partners lp has  invested in immunomedics inc nasdaqimmu for  million shares massmutual tru fsb adv accumulated  shares legal  general gp plc reported  shares morgan stanley owns  invested in immunomedics inc nasdaqimmu for  shares tiaa cref inv limited liability company stated it has  shares or  of all its holdings  are owned by  capital limited liability company vanguard holds  of its portfolio in immunomedics inc nasdaqimmu for  million shares ubs asset mgmt americas holds  or  shares in its portfolio weiss multi a alabamabased fund reported  shares deutsche retail bank ag holds  shares or  of its portfolio meeder asset inc reported  shares among  analysts covering immunomedics nasdaqimmu  have buy rating  sell and  hold therefore  are positive immunomedics had  analyst reports since july   according to sratingsintel the firm has “buy” rating by jefferies given on thursday october  the firm has “market perform” rating by wells fargo given on tuesday june  jefferies maintained immunomedics inc nasdaqimmu rating on friday june  jefferies has “buy” rating and  target the company was downgraded on friday december  by wells fargo the company was upgraded on friday may  by jefferies as per tuesday march  the company rating was maintained by jefferies the firm has “hold” rating given on wednesday july  by jefferies the stock of immunomedics inc nasdaqimmu has “buy” rating given on monday july  by cowen  co sabby management llc increased intellia therapeutics inc stake by  shares to  valued at m in q it also upped fibrogen inc call stake by  shares and now owns  shares la jolla pharmaceutical co nasdaqljpc was raised too analysts await immunomedics inc nasdaqimmu to report earnings on august  they expect  earnings per share up  or  from last year’s  per share after  actual earnings per share reported by immunomedics inc for the previous quarter wall street now forecasts  eps growth by marie mckinney echostar corporationreceive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with our free daily email newsletter free newsletter enter your email address below to get the latest news and analysts ratings for your stocks with our free daily email newsletter recent posts public storage psa reaches  yearly low juniper networks jnpr shorts raised by  johnson controls international plc ordinary share jci reaches  yearly low jounce therapeutics jnce shorts increased by  adverum biotechnologies advm analysts see  eps highvista strategies has lifted cheniere energy lng stake bemis company inc bms reaches   week low green valley investors cut by  million its air products  chemicals apd stake t biosystems ttoo analysts see  eps last week american assets trust aat coverage threshold pharmaceuticals inc thld analysts see  eps bowen hanes  co upped by  million its vulcan materials vmc stake fukoku mutual life insurance company has cut nextera energy nee holding by   analysts bullish eaton corporation plc ordinary shares etn norinchukin bank the upped costco whsl new cost position last week chipotle mexican grill inc cmg analysts liveperson inc lpsn reaches  week high shorts at jazz pharmaceuticals plc ireland jazz raised by  the providence service prsc analysts see  eps shorts at ja solar holdings company limited ads jaso lowered by   copyright  bibey post inc  bibeypostcom       about  our team  contact ocular therapeutix ocul eps estimated at  sabby management has trimmed its immunomedics immu holding  bibey post trending stock news penny stock news market news stock news ocular therapeutix ocul eps estimated at  sabby management has trimmed its immunomedics immu holding july    by marie mckinney sabby management llc decreased immunomedics inc immu stake by  reported in q sec filing sabby management llc sold  shares as immunomedics inc immu’s stock rose  the sabby management llc holds  shares with  value down from  last quarter immunomedics inc now has m valuation the stock rose  or  reaching  about  shares traded immunomedics inc nasdaqimmu has risen  since july   and is uptrending it has outperformed by  the sp analysts expect ocular therapeutix inc nasdaqocul to report  eps on august they anticipate  eps change or  from last quarter’s  eps after having  eps previously ocular therapeutix inc’s analysts see  eps growth about  shares traded ocular therapeutix inc nasdaqocul has declined  since july   and is downtrending it has underperformed by  the sp among  analysts covering ocular therapeutix nasdaqocul  have buy rating  sell and  hold therefore  are positive ocular therapeutix had  analyst reports since august   according to sratingsintel cantor fitzgerald maintained the shares of ocul in report on monday july  with “buy” rating on friday february  the stock rating was initiated by cantor fitzgerald with “overweight” morgan stanley downgraded the shares of ocul in report on friday june  to “equalweight” rating nomura initiated the shares of ocul in report on wednesday august  with “buy” rating on friday october  the stock rating was downgraded by morgan stanley to “equalweight” the rating was initiated by morgan stanley with “equal weight” on thursday august  morgan stanley upgraded it to “overweight” rating and  target in thursday february  report btig research maintained the shares of ocul in report on tuesday july  with “hold” rating jmp securities initiated the shares of ocul in report on thursday august  with “outperform” rating morgan stanley maintained it with “overweight” rating and  target in thursday april  report ocular therapeutix inc is a biopharmaceutical company the company has market cap of  million the firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology it currently has negative earnings the company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye investors sentiment increased to  in q  its up  from  in q it increased as  investors sold immu shares while  reduced holdings  funds opened positions while  raised stakes  million shares or  more from  million shares in q were reported  million are owned by state street corp  million are held by everpoint asset ltd blackrock advisors lc accumulated  or  shares j goldman co lp holds  of its portfolio in immunomedics inc nasdaqimmu for  shares tourbillon capital partners lp has  invested in immunomedics inc nasdaqimmu for  million shares massmutual tru fsb adv accumulated  shares legal  general gp plc reported  shares morgan stanley owns  invested in immunomedics inc nasdaqimmu for  shares tiaa cref inv limited liability company stated it has  shares or  of all its holdings  are owned by  capital limited liability company vanguard holds  of its portfolio in immunomedics inc nasdaqimmu for  million shares ubs asset mgmt americas holds  or  shares in its portfolio weiss multi a alabamabased fund reported  shares deutsche retail bank ag holds  shares or  of its portfolio meeder asset inc reported  shares among  analysts covering immunomedics nasdaqimmu  have buy rating  sell and  hold therefore  are positive immunomedics had  analyst reports since july   according to sratingsintel the firm has “buy” rating by jefferies given on thursday october  the firm has “market perform” rating by wells fargo given on tuesday june  jefferies maintained immunomedics inc nasdaqimmu rating on friday june  jefferies has “buy” rating and  target the company was downgraded on friday december  by wells fargo the company was upgraded on friday may  by jefferies as per tuesday march  the company rating was maintained by jefferies the firm has “hold” rating given on wednesday july  by jefferies the stock of immunomedics inc nasdaqimmu has “buy” rating given on monday july  by cowen  co sabby management llc increased intellia therapeutics inc stake by  shares to  valued at m in q it also upped fibrogen inc call stake by  shares and now owns  shares la jolla pharmaceutical co nasdaqljpc was raised too analysts await immunomedics inc nasdaqimmu to report earnings on august  they expect  earnings per share up  or  from last year’s  per share after  actual earnings per share reported by immunomedics inc for the previous quarter wall street now forecasts  eps growth by marie mckinney echostar corporationreceive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with our free daily email newsletter free newsletter enter your email address below to get the latest news and analysts ratings for your stocks with our free daily email newsletter recent posts public storage psa reaches  yearly low juniper networks jnpr shorts raised by  johnson controls international plc ordinary share jci reaches  yearly low jounce therapeutics jnce shorts increased by  adverum biotechnologies advm analysts see  eps highvista strategies has lifted cheniere energy lng stake bemis company inc bms reaches   week low green valley investors cut by  million its air products  chemicals apd stake t biosystems ttoo analysts see  eps last week american assets trust aat coverage threshold pharmaceuticals inc thld analysts see  eps bowen hanes  co upped by  million its vulcan materials vmc stake fukoku mutual life insurance company has cut nextera energy nee holding by   analysts bullish eaton corporation plc ordinary shares etn norinchukin bank the upped costco whsl new cost position last week chipotle mexican grill inc cmg analysts liveperson inc lpsn reaches  week high shorts at jazz pharmaceuticals plc ireland jazz raised by  the providence service prsc analysts see  eps shorts at ja solar holdings company limited ads jaso lowered by   copyright  bibey post inc  bibeypostcom       about  our team  contact the klein law firm reminds investors of a class action filed on behalf of ocular therapeutix inc shareholders and a lead plaintiff deadline of september    business wire the klein law firm reminds investors of a class action filed on behalf of ocular therapeutix inc shareholders and a lead plaintiff deadline of september   july    am eastern daylight time new yorkbusiness wirethe klein law firm announces that a class action complaint has been filed on behalf of shareholders of ocular therapeutix inc nasdaq ocul who purchased shares between may   and july   the action which was filed in the united states district court for the district of new jersey alleges that the company violated federal securities laws in particular the complaint alleges that throughout the class period defendants made materially false andor misleading statements andor failed to disclose that  ocular therapeutixs management has been misleading investors about dextenza manufacturing issues including that more than  of lots manufactured by ocular therapeutix contain bad product  such manufacturing issues could impact the approval of dextenza by the fda and  as a result defendants’ public statements were materially false and misleading shareholders have until september   to petition the court for lead plaintiff status your ability to share in any recovery does not require that you serve as lead plaintiff you may choose to be an absent class member if you suffered a loss during the class period and wish to obtain additional information please contact joseph klein esq by telephone at  or visit httpwwwkleinstocklawcompslrasboculartherapeutixincwire joseph klein esq is an experienced attorney and has also practiced as a certified public accountant mr klein represents investors and participates in securities litigations involving financial fraud throughout the nation attorney advertising prior results do not guarantee similar outcomes contacts the klein law firmjoseph klein esq fax wwwkleinstocklawcom release summary the klein law firm reminds investors that a class action complaint has been filed on behalf of shareholders of ocular therapeutix inc contacts the klein law firmjoseph klein esq fax wwwkleinstocklawcom search advanced news search advanced news search log in sign up the klein law firm reminds investors of a class action filed on behalf of ocular therapeutix inc shareholders and a lead plaintiff deadline of september    business wire the klein law firm reminds investors of a class action filed on behalf of ocular therapeutix inc shareholders and a lead plaintiff deadline of september   july    am eastern daylight time new yorkbusiness wirethe klein law firm announces that a class action complaint has been filed on behalf of shareholders of ocular therapeutix inc nasdaq ocul who purchased shares between may   and july   the action which was filed in the united states district court for the district of new jersey alleges that the company violated federal securities laws in particular the complaint alleges that throughout the class period defendants made materially false andor misleading statements andor failed to disclose that  ocular therapeutixs management has been misleading investors about dextenza manufacturing issues including that more than  of lots manufactured by ocular therapeutix contain bad product  such manufacturing issues could impact the approval of dextenza by the fda and  as a result defendants’ public statements were materially false and misleading shareholders have until september   to petition the court for lead plaintiff status your ability to share in any recovery does not require that you serve as lead plaintiff you may choose to be an absent class member if you suffered a loss during the class period and wish to obtain additional information please contact joseph klein esq by telephone at  or visit httpwwwkleinstocklawcompslrasboculartherapeutixincwire joseph klein esq is an experienced attorney and has also practiced as a certified public accountant mr klein represents investors and participates in securities litigations involving financial fraud throughout the nation attorney advertising prior results do not guarantee similar outcomes contacts the klein law firmjoseph klein esq fax wwwkleinstocklawcom release summary the klein law firm reminds investors that a class action complaint has been filed on behalf of shareholders of ocular therapeutix inc contacts the klein law firmjoseph klein esq fax wwwkleinstocklawcom search advanced news search advanced news search log in sign up a statement released earlier today by hc wainwright about ocular therapeutix ndaqocul bumps the target price to  headlines business technology economy personal finance menuheadlines business technology economy personal finance dont miss peet’s buys majority stake in another coffee chain walgreen records q loss as expected ebay plans to spin off paypal tibco taken private by vista equity for  billion athlon energy athl up big on buyout news dave  buster’s ipo terms set  per share home  investing  a statement released earlier today by hc wainwright about ocular therapeutix ndaqocul bumps the target price to  a statement released earlier today by hc wainwright about ocular therapeutix ndaqocul bumps the target price to  by al wild updated july   stating a potential upside of  hc wainwright upped the price target of ocular therapeutix ndaqocul to  on wednesday july   cantor fitzgerald released a statement on ocular therapeutix ndaqocul dropped the target price from  to  that suggested an upside of  having a price of  ocular therapeutix ndaqocul traded  lower on the day with the last close down  from the two hundred day average compared with the sp  index which has increased  over the same period ocular therapeutix has recorded a day average of  and a two hundred day average of  volume of trade was down over the average with  shares of ocul changing hands under the typical  recent performance chart ocular therapeutix has  week low of  and a  week high of  and has a market capitalization of  in addition to hc wainwright reporting its stock price target a total of  brokers have issued a research note on the company the average stock price target is  with  broker rating the stock a strong buy  brokers rating the stock a buy  brokers rating the stock a hold  brokers rating the stock a underperform and finally  brokers rating the stock a sell brief synopsis on ocular therapeutix ndaqocul ocular therapeutix inc is a biopharmaceutical company the company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology the companys bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye its lead product candidates are dextenza dexamethasone insert for the treatment of postsurgical ocular inflammation and pain allergic conjunctivitis and dry eye disease and otxtp for the treatment of glaucoma and ocular hypertension which are extendeddelivery drugeluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose it also has an intravitreal hydrogel depot which is in preclinical development for the treatment of diseases and conditions of the back of the eye including wet agerelated macular degeneration wet amd receive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with marketbeatcoms free daily email newsletter leave a reply cancel reply your email address will not be published required fields are marked comment name  email  website more news mosaic capital corp tsem target dropped to  released a report earlier today by canaccord genuity stating a potential downside of  mobile telesystems nysembt has been upgraded from neutral to overweight in a report by jp morgan today just yesterday mobile telesystems nysembt traded a statement released earlier today by gmp securities about prairiesky royalty tsepsk bumps the target price to  gmp securities upped the price target a report released today by national bank financial about mullen group tsemtl raises the target price to  in a report released on wednesday norsk hydro nysenhydy has been upgraded from neutral to outperform in a statement by credit suisse earlier today boasting a price of  norsk deutsche bank downgraded merck kgaa otcmkgay from buy to hold in a statement released earlier today deutsche bank has downgraded merck kgaa qiwi nyseqiwi has been downgraded from buy to neutral in a statement by citigroup earlier today just yesterday qiwi nyseqiwi traded  news corp ndaqnws has been upgraded from neutral to buy in a statement by citigroup earlier today citigroup has upgraded news corp ndaqnws a statement released earlier today by hc wainwright about ocular therapeutix ndaqocul bumps the target price to  stating a potential upside of  newmont mining corporation tsenem target price raised to  issued a report today by scotia capital newmont mining corporation tsenem had its about breaking finance news contributors contact privacy policy copyright   breaking finance news a statement released earlier today by hc wainwright about ocular therapeutix ndaqocul bumps the target price to  headlines business technology economy personal finance menuheadlines business technology economy personal finance dont miss peet’s buys majority stake in another coffee chain walgreen records q loss as expected ebay plans to spin off paypal tibco taken private by vista equity for  billion athlon energy athl up big on buyout news dave  buster’s ipo terms set  per share home  investing  a statement released earlier today by hc wainwright about ocular therapeutix ndaqocul bumps the target price to  a statement released earlier today by hc wainwright about ocular therapeutix ndaqocul bumps the target price to  by al wild updated july   stating a potential upside of  hc wainwright upped the price target of ocular therapeutix ndaqocul to  on wednesday july   cantor fitzgerald released a statement on ocular therapeutix ndaqocul dropped the target price from  to  that suggested an upside of  having a price of  ocular therapeutix ndaqocul traded  lower on the day with the last close down  from the two hundred day average compared with the sp  index which has increased  over the same period ocular therapeutix has recorded a day average of  and a two hundred day average of  volume of trade was down over the average with  shares of ocul changing hands under the typical  recent performance chart ocular therapeutix has  week low of  and a  week high of  and has a market capitalization of  in addition to hc wainwright reporting its stock price target a total of  brokers have issued a research note on the company the average stock price target is  with  broker rating the stock a strong buy  brokers rating the stock a buy  brokers rating the stock a hold  brokers rating the stock a underperform and finally  brokers rating the stock a sell brief synopsis on ocular therapeutix ndaqocul ocular therapeutix inc is a biopharmaceutical company the company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology the companys bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye its lead product candidates are dextenza dexamethasone insert for the treatment of postsurgical ocular inflammation and pain allergic conjunctivitis and dry eye disease and otxtp for the treatment of glaucoma and ocular hypertension which are extendeddelivery drugeluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose it also has an intravitreal hydrogel depot which is in preclinical development for the treatment of diseases and conditions of the back of the eye including wet agerelated macular degeneration wet amd receive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with marketbeatcoms free daily email newsletter leave a reply cancel reply your email address will not be published required fields are marked comment name  email  website more news mosaic capital corp tsem target dropped to  released a report earlier today by canaccord genuity stating a potential downside of  mobile telesystems nysembt has been upgraded from neutral to overweight in a report by jp morgan today just yesterday mobile telesystems nysembt traded a statement released earlier today by gmp securities about prairiesky royalty tsepsk bumps the target price to  gmp securities upped the price target a report released today by national bank financial about mullen group tsemtl raises the target price to  in a report released on wednesday norsk hydro nysenhydy has been upgraded from neutral to outperform in a statement by credit suisse earlier today boasting a price of  norsk deutsche bank downgraded merck kgaa otcmkgay from buy to hold in a statement released earlier today deutsche bank has downgraded merck kgaa qiwi nyseqiwi has been downgraded from buy to neutral in a statement by citigroup earlier today just yesterday qiwi nyseqiwi traded  news corp ndaqnws has been upgraded from neutral to buy in a statement by citigroup earlier today citigroup has upgraded news corp ndaqnws a statement released earlier today by hc wainwright about ocular therapeutix ndaqocul bumps the target price to  stating a potential upside of  newmont mining corporation tsenem target price raised to  issued a report today by scotia capital newmont mining corporation tsenem had its about breaking finance news contributors contact privacy policy copyright   breaking finance news pipeline ocular therapeutix inc ocular therapeutix inc  product candidatesproduct candidates product candidates dextenza™ otxtp travoprost insert intravitreal depots top ocular therapeutix inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports ocular therapeutix inc  product pipeline review   ocular therapeutix inc  product pipeline review   wgr  november  global  pages global markets direct description table of content sample report enquiry before buy related reports ocular therapeutix inc  product pipeline review  summaryglobal markets direct’s ‘ocular therapeutix inc  product pipeline review  ’ provides an overview of the ocular therapeutix inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of ocular therapeutix inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of ocular therapeutix inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of ocular therapeutix inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the ocular therapeutix inc’s pipeline productsreasons to buy evaluate ocular therapeutix inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of ocular therapeutix inc in its therapy areas of focus identify new drug targets and therapeutic classes in the ocular therapeutix inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of ocular therapeutix inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of ocular therapeutix inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of ocular therapeutix inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures ocular therapeutix inc snapshot ocular therapeutix inc overview key information key facts ocular therapeutix inc  research and development overview key therapeutic areas ocular therapeutix inc  pipeline review pipeline products by stage of development pipeline products  monotherapy ocular therapeutix inc  pipeline products glance ocular therapeutix inc  late stage pipeline products phase iii productscombination treatment modalities ocular therapeutix inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities ocular therapeutix inc  early stage pipeline products preclinical productscombination treatment modalities ocular therapeutix inc  drug profiles dexamethasone acetate sr product description mechanism of action rd progress travoprost sr product description mechanism of action rd progress moxifloxacin hydrochloride sr product description mechanism of action rd progress protein to inhibit vegf for ophthalmology product description mechanism of action rd progress ocular therapeutix inc  pipeline analysis ocular therapeutix inc  pipeline products by target ocular therapeutix inc  pipeline products by route of administration ocular therapeutix inc  pipeline products by molecule type ocular therapeutix inc  pipeline products by mechanism of action ocular therapeutix inc  recent pipeline updates ocular therapeutix inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesocular therapeutix inc key information ocular therapeutix inc key facts ocular therapeutix inc  pipeline by indication  ocular therapeutix inc  pipeline by stage of development  ocular therapeutix inc  monotherapy products in pipeline  ocular therapeutix inc  phase iii  ocular therapeutix inc  phase ii  ocular therapeutix inc  phase i  ocular therapeutix inc  preclinical  ocular therapeutix inc  pipeline by target  ocular therapeutix inc  pipeline by route of administration  ocular therapeutix inc  pipeline by molecule type  ocular therapeutix inc  pipeline products by mechanism of action  ocular therapeutix inc  recent pipeline updates  list of figuresocular therapeutix inc  pipeline by top  indication  ocular therapeutix inc  pipeline by stage of development  ocular therapeutix inc  monotherapy products in pipeline  ocular therapeutix inc  pipeline by top  target  ocular therapeutix inc  pipeline by top  route of administration  ocular therapeutix inc  pipeline by top  molecule type  ocular therapeutix inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send oculnasdaq gm stock quote  ocular therapeutix inc  bloomberg markets error could not add to watchlist x  watchlist ocular therapeutix inc oculus nasdaq gm usd   as of  am edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases  oculars dextenza reports positive study results  investopedia  regeneron ocular to develop eye drug regn ocul  investopedia  ocular therapeutix ocul stock soars on regeneron deal  the street there are currently no news stories for this ticker please check back later  minutes ago shareholder alert bronstein gewirtz  grossman llc notifies investors of class action against ocular therapeutix inc ocul  the klein law firm reminds investors of a class action filed on behalf of ocular therapeutix inc shareholders and a lead  block  leviton reminds ocular therapeutix inc ocul shareholders of important deadline in securities fraud class action and  ocul investors update hagens berman alerts investors in ocular therapeutix inc to expanded class period in pending securitie  the klein law firm announces a class action filed on behalf of ocular therapeutix inc shareholders and a lead plaintiff  lifshitz  miller llp announces investigation of acacia communications inc angiodynamics inc clubcorp holdings inc hd  the klein law firm notifies investors of an investigation concerning possible violations of federal securities laws by ocular  diabetic macular edema pipeline therapeutics companies and drugs profile insights  available at rnr market research  shareholder alert pomerantz law firm reminds shareholders with losses on their investment in ocular therapeutix inc of class  ocul investor alert the law offices of vincent wong reminds investors of a class action involving ocular therapeutix inc and there are currently no press releases for this ticker please check back later profile ocular therapeutix inc develops and markets eye care products the company offers ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet and underserved needs in ophthalmology ocular therapeutix serves customers worldwide address  crosby drivesuite bedford ma united states phone  website wwwocutxcom executives board members amarpreet sawhney chairmanpresidentceo antony mattessich chief executive officer george v migausky interim cfo james fortune chief operating officer andy hurley chief commercial officer show more ocul key statistics  ocular therapeutix inc financial ratios  marketwatch bulletin investor alert london markets close in currencies futures metals stocks expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close ocular therapeutix inc nasdaq ocul go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus ocular therapeutix inc market open  real time quotes jul    am ocul quoteszigmancomposite   change   volume volume  real time quotes quoteszigmancomposite previous close     change   day low day high    week low  week high   company description ocular therapeutix inc is a biopharmaceutical company which engages in the development and commercialization of therapies for diseases and conditions of the eye its products include dextenza sustained release travopost and posterior segment injections the company was founded by amarpreet s s ocular therapeutix inc is a biopharmaceutical company which engages in the development and commercialization of therapies for diseases and conditions of the eye its products include dextenza sustained release travopost and posterior segment injections the company was founded by amarpreet s sawhney and farhad khosravi on september   and is headquartered in bedford ma valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title dr amarpreet s sawhney   chairman president  chief executive officer mr james fortune   chief accounting  operating officer mr george v migausky   chief financial officer dr jonathan h talamo   chief medical officer dr peter jarrett   chief scientific officer insider actions – purchase – sale  – number of transactions  date name shares transaction value  james fortune chief operating officer    disposition at  per share   versant venture management llc    disposition at  per share   versant venture management llc    disposition at  per share   versant venture management llc    disposition at  per share   versant venture management llc    disposition at  per share   versant venture management llc    disposition at  per share   versant venture management llc    disposition at  per share   versant venture management llc    disposition at  per share   versant venture management llc    disposition at  per share   sv health investors llc    disposition at  per share   sv health investors llc    disposition at  per share   sv health investors llc    disposition at  per share   sv health investors llc    disposition at  per share   richard l lindstrom director    derivativenonderivative trans at  per share   richard l lindstrom director    derivativenonderivative trans at  per share   polaris partners    disposition at  per share   polaris partners    disposition at  per share   polaris partners    disposition at  per share   polaris partners    disposition at  per share   versant venture management llc    derivativenonderivative trans at  per share   versant venture management llc    derivativenonderivative trans at  per share   versant venture management llc    derivativenonderivative trans at  per share   versant venture management llc    derivativenonderivative trans at  per share   sv health investors llc    derivativenonderivative trans at  per share   sv health investors llc    derivativenonderivative trans at  per share   sv health investors llc    derivativenonderivative trans at  per share   sv health investors llc    derivativenonderivative trans at  per share   ascension ventures llc    derivativenonderivative trans at  per share   ascension ventures llc    derivativenonderivative trans at  per share   jaswinder s chadha director    derivativenonderivative trans at  per share   richard l lindstrom director    derivativenonderivative trans at  per share   sv health investors llc    acquisition at  per share   sv health investors llc    acquisition at  per share   sv health investors llc    acquisition at  per share   sv health investors llc    acquisition at  per share   ascension ventures llc    acquisition at  per share   eric ankerud see remarks    acquisition at  per share  newslatestcompanyusocul marketwatch news on ocul news from the north buying these commodity stocks looks like a home run  am july    victor reklaitis ocular therapeutix shares plummet after fda pushes back on eyedrug approval  pm july    wallace witkowski ocular therapeutix shares rally after company submits fda amendment  pm july    claudia assis ocular therapeutix downgraded to equal weight at morgan stanley  am june    tomi kilgore ocular therapeutix surges  on positive early clinical trial results  am nov    emma court ocular therapeutix stock surges  on positive topline results for latestage eye treatment  am nov    emma court ocular therapeutix stock up  on  mln regeneron drug development deal  am oct    emma court ocular therapeutix stock jumps  after regeneron drug development deal announcement  am oct    emma court ocular stock drops  after eye pain drug fails to get fda approval  am july    emma court this stock’s crash is a cautionary tale on the dangers of betting on biotech ipos  am june    caitlin huston sp  logs best  close as yellen plays down jobs report  pm june    joseph adinolfi ocular therapeutixs stock resumes trade plummets  premarket after trial results disappoint  am june    tomi kilgore ocular therapeutixs latestage trial of pink eye treatments fails to meet objective  am june    tomi kilgore ocular therapeutixs phase  trial of pink eye treatment failed to achieve primary endpoint  am june    tomi kilgore ocular therapeutix stock halted for news  am june    tomi kilgore  stocks to watch  pm april    the trading deck ocular therapeutixs stock rockets  premarket after upbeat trial outlook  am feb    tomi kilgore some ‘cheap’ biotech stocks that could be buyout targets rbc says  pm jan    emma court almost half of venturebacked ipos this year are losers  am oct    philip van doorn newsnonmarketwatchcompanyusocul other news on ocul premarket analyst action  healthcare  am july    seeking alpha oculars poke in the other eye  am july    seeking alpha biotech forum daily digest  new leadership at teva a trading idea for agenus  am july    seeking alpha why ocular theraputix inc saw its stock price plummet today  pm july    motley fool btig shares two cents on ocular therapeutix inc ocul following crl for dextenza  pm july    smarteranalyst ocular therapeutix receives crl creates bonus short opportunity  am july    seeking alpha why cantor just slashed the price target for ocular therapeutix inc ocul  am july    smarteranalyst biotech stock roundup arena shoots up on study data celg inks immunooncology deal  am july    zackscom cantor remains confident on ocular therapeutix despite big decline  am july    benzingacom ocular therapeutix falls  after major setback in dextenza  am july    benzingacom ocular therapeutix  as fda denies nda for dextenza  pm july    seeking alpha heres why ocular therapeutix inc rose  today  pm july    motley fool biotech forum daily digest  fda blesses amicus therapeutics  ocular therapeutix rebounds  am july    seeking alpha premarket gainers as of  am  am july    seeking alpha ocular therapeutix inc ocul soars  after making move to resolve dextenza manufacturing issues cantor weighs in  am july    smarteranalyst ocular submits amendment to dextenza nda for equipment change closes out form  issues fda action date october  shares ahead  after hours  pm july    seeking alpha why ocular therapeutix inc got beat down today  pm july    motley fool ocular a poke in the eye  pm july    seeking alpha biotech forum daily digest  biotech fritters away some gains  fda calendar events in july  am july    seeking alpha key fda events to watch out for in jul   am july    zackscom loading more headlines at a glance ocular therapeutix inc  crosby drive suite  bedford massachusetts  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for ocul newspressreleasecompanyusocul press releases on ocul shareholder alert bronstein gewirtz  grossman llc notifies investors of class action against ocular therapeutix inc ocul  lead plaintiff deadline september    min ago am july    globenewswire equity alert khang  khang llp announces a securities class action lawsuit against ocular therapeutix inc and encourages investors with losses to contact the firm  pm july    accesswire the klein law firm reminds investors of a class action filed on behalf of ocular therapeutix inc shareholders and a lead plaintiff deadline of september    am july    businesswire  bzx shareholder alert pomerantz law firm reminds shareholders with losses on their investment in ocular therapeutix inc of class action lawsuit and upcoming deadline  ocul  pm july    accesswire block  leviton reminds ocular therapeutix inc ocul shareholders of important deadline in securities fraud class action and encourages them to contact the firm  pm july    pr newswire  prf ocul investors update hagens berman alerts investors in ocular therapeutix inc to expanded class period in pending securities class action reminds them of the september   lead plaintiff deadline and updates them about possible disclosure problems concerning otxtp factors  pm july    pr newswire  prf important shareholder alert lundin law pc announces securities class action lawsuit against ocular therapeutix inc and reminds investors with losses to contact the firm  pm july    accesswire the klein law firm announces a class action filed on behalf of ocular therapeutix inc shareholders and a lead plaintiff deadline of september    pm july    businesswire  bzx pawar law group announces filing of securities class action lawsuit against ocular therapeutix inc  ocul  pm july    accesswire lifshitz  miller llp announces investigation of acacia communications inc angiodynamics inc clubcorp holdings inc hd supply holdings inc ocular therapeutix inc repros therapeutics inc and tahoe resources inc  pm july    pr newswire  prf the klein law firm notifies investors of an investigation concerning possible violations of federal securities laws by ocular therapeutix inc ocul  am july    businesswire  bzx shareholder alert pomerantz law firm reminds shareholders with losses on their investment in ocular therapeutix inc of class action lawsuit and upcoming deadline  ocul  pm july    pr newswire  prf shareholder alert khang  khang llp announces a securities class action lawsuit against ocular therapeutix inc and encourages investors with losses to contact the firm  pm july    accesswire ocul shareholder alert the law offices of vincent wong notifies investors of commencement of a class action involving ocular therapeutix inc and a lead plaintiff deadline of september    am july    businesswire  bzx ocular therapeutix alert faruqi  faruqi llp encourages investors who suffered losses exceeding  in ocular therapeutix inc to contact the firm  pm july    pr newswire  prf equity alert lundin law pc announces securities class action lawsuit against ocular therapeutix inc and encourages investors with losses to contact the firm  pm july    accesswire shareholder alert bronstein gewirtz  grossman llc notifies investors of class action against ocular therapeutix inc ocul  lead plaintiff deadline september    am july    accesswire shareholder alert pomerantz law firm reminds shareholders with losses on their investment in ocular therapeutix inc of class action lawsuit and upcoming deadline  ocul  pm july    accesswire important equity alert khang  khang llp announces a securities class action lawsuit against ocular therapeutix inc and encourages investors with losses to contact the firm  pm july    accesswire shareholder alert levi  korsinsky llp notifies shareholders of ocular therapeutix inc of a class action lawsuit and a lead plaintiff deadline of september    am july    businesswire  bzx loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york open marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest agold flirts with highest level in weeks ahere’s what it looks like when the foreclosure ‘pig’ moves through the housingcrisis ‘python’ avirtual reality is about to go mainstream as htc beats facebook and lenovo to market asean spicer could make six figures by going back on tv adisney shuts down vacation savings accounts — and offers  bonus for remaining customers astock market sets another round of records as facebook rallies aeia reports a smallerthanexpected rise in us naturalgas supplies ascaramucci says trump’s love of cheeseburgers shows he’s not an elitist —  ways rich people act like everyone else awhy equalweighted stockmarket indexes bounce back faster from bear markets aeia reports weekly rise of  bln cubic feet in us naturalgas supplies aaugust natural gas at mln btus up from  before supply data afor transgender americans workplace discrimination isn’t limited to the military abuzzfeed launches app and cooktop product for popular video cooking series tasty awhen should you make ‘course corrections’ to your retirement plan a‘game of thrones’ new photos of episode  tease meeting of fire and ice aprocter  gamble profit climbs amid proxy fight afiat chrysler profit buoyed by sports cars amastercard tops estimates as consumer spend more ahow the fed’s big balance sheet unwind may affect markets astarbucks earnings wellpositioned for global growth but samestore sales a concern loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  ocular therapeutix inc tollfree   call for information about pending cases – at no cost toggle navigation join a class action about attorneys contact faq class action cases view complaint retainer agreement infopawarlawgroupcom ocular’s management has been misleading investors about dextenza manufacturing issues including that more than  of lots manufactured by ocular contain bad product click join this class action above attorneys vik pawar esq ocular therapeutix inc join class action » the pawar law group announces a class action lawsuit on behalf of general cable corporation bgc investors who purchased general cable stock between may   and july   inclusive the “class period” the suit is for recovery of investor losses no class has been certified in the above action yet until certification occurs you are not represented by an attorney you may choose to take no action and remain a passive class member press release according to the complaint throughout the class period defendants made false andor misleading statements andor failed to disclose that  ocular’s management has been misleading investors about dextenza manufacturing issues including that more than  of lots manufactured by ocular contain bad product  such manufacturing issues could imperil the approval of dextenza by the fda and  as a result defendants’ public statements were materially false and misleading at all relevant times on july   seeking alpha published an article concerning dextenza manufacturing issues on that same day stat published an article asserting that dextenza could be rejected by the fda because of product contamination on this news shares of ocular therapeutix fell  per share or over  over two trading days to close at  per share on july   damaging investors on july   ocular disclosed that it received a complete response letter from the fda stating “that the fda has determined that it cannot approve the nda in its present form” on this news shares of ocular fell  per share or over  to close at  per share on july   further damaging investors if you wish to serve as lead plaintiff you must move the court no later than september   a lead plaintiff is a representative party acting on behalf of other class members in directing the litigation you may join the case here httppawarlawgroupcomcasesocular or email vik pawar esq at vikpawarlawgroupcom —————————— contact vik pawar esq pawar law group  vesey street suite  new york ny  tel   fax   vikpawarlawgroupcom ocular therapeutix inc ocula company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile ocular therapeutix inc ocula related topics stocksstock screenerhealthcaremedical equipment supplies  distribution overview news key developments people charts financials analysts research pulse ocula on american stock exchange usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description ocular therapeutix inc incorporated on september   is a biopharmaceutical company the company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology the companys bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye its lead product candidates are dextenza dexamethasone insert for the treatment of postsurgical ocular inflammation and pain allergic conjunctivitis and dry eye disease and otxtp for the treatment of glaucoma and ocular hypertension which are extendeddelivery drugeluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose it also has an intravitreal hydrogel depot which is in preclinical development for the treatment of diseases and conditions of the back of the eye including wet agerelated macular degeneration wet amddextenza incorporates the food and drug administration fdaapproved corticosteroid dexamethasone as an active pharmaceutical ingredient into a hydrogelbased drugeluting insert for intracanalicular use dextenza is also in phase iii clinical development for the treatment of allergic conjunctivitis dextenza is in phase ii clinical development for the treatment of dry eye disease otxtp incorporates travoprost which is an fdaapproved prostaglandin analogue in eye drop form that reduces elevated intraocular pressure iop as its active pharmaceutical ingredient into a hydrogelbased drugeluting intracanalicular insert otxtp is being developed as a treatment for glaucoma and ocular hypertension it is engaged in the preclinical development of its hydrogel depot administered through intravitreal injection its product resure sealant is a topical liquid hydrogel that creates a temporary adherent soft and lubricious sealant to prevent postsurgical leakage from clear corneal incisions that are made during cataract surgery resure sealant is approved to seal corneal incisions following cataract surgerythe company competes with icon biosciences inc inotek pharmaceuticals allergan inc forsight vision mati therapeutics invisia therapeutics and beaver visitec » full overview of ocula company address ocular therapeutix inc  crosby dr ste bedford   ma    p f  company web links home page officers  directors name compensation amarpreet sawhney  antony mattessich  james fortune  george migausky  eric ankerud  » more officers  directors ocular therapeutix inc news briefocular therapeutix submits amendment to potentially extend review for dextenza nda jul   briefocular therapeutix announces executive transition plans jun   briefocular therapeutix presents additional phase  data results for dextenza may   briefocular therapeutix reports q loss per share of  may   briefocular therapeutix bradford smith notified on march  of his resignation from his position as cfo effective march   mar   » more ocula news related topics stocksstock screenerhealthcaremedical equipment supplies  distribution ocular therapeutix inc nasdaqocul quotes  news  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinanceocular therapeutix incnasdaqoculadd to portfoliocompanysummarynewsrelated companieshistorical pricesfinancialsmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   ocular therapeutix inc  public nasdaqocul   watch this stock      realtime   am edt nasdaq realtime data  disclaimer currency in usd range     week    open  vol  avg m mkt cap m pe      divyield      eps  shares m beta      inst own  news relevance date all news for ocular therapeutix inc » subscribe advertisement events add ocul to my calendars aug   q  ocular therapeutix inc earnings release estimated  am edt  jul   ocular therapeutix inc corporate conference call  jun   ocular therapeutix inc at jmp securities life science conference jun   ocular therapeutix inc at jefferies healthcare conference jun   ocular therapeutix inc annual shareholders meeting may   q  ocular therapeutix inc earnings release may   q  ocular therapeutix inc earnings call  more events from dailyfinance »     key stats and ratios q mar   net profit margin   operating margin   ebitd margin   return on average assets   return on average equity   employees   cdp score   screen stocks with similar metrics » address  crosby dr ste bedford ma united states  map phone fax website links httpwwwocutxcom external links analyst estimates  marketwatch sec filings  edgar online major holders  msn money research reports  reuters settings  technicals  link to this view volume delayed by  minsprices are not from all markets sources include six advertisement related companies show most recent quarter most recent annual add or remove columns save changes cancel sector healthcare  industry medical equipment supplies  distribution  nec more from factset » description ocular therapeutix inc is a biopharmaceutical company the company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology the companys bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye its lead product candidates are dextenza dexamethasone insert for the treatment of postsurgical ocular inflammation and pain allergic conjunctivitis and dry eye disease and otxtp for the treatment of glaucoma and ocular hypertension which are extendeddelivery drugeluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose it also has an intravitreal hydrogel depot which is in preclinical development for the treatment of diseases and conditions of the back of the eye including wet agerelated macular degeneration wet amd more from reuters » officers and directors amarpreet sawhney phd executive chairman of the board age  bio  compensation   reuters antony charles mattessich president chief executive officer director age  bio  compensation   reuters james fortune interim principal financial officer chief operating officer interim princiapl accounting officer age  bio  compensation   reuters george v migausky interim chief financial officer age  bio  compensation   reuters eric p ankerud executive vice president regulatory quality and compliance age  bio  compensation   reuters andy hurley chief commercial officer age  bio  compensation   reuters jonathan talamo md chief medical officer age  bio  compensation   reuters jaswinder s chadha director age  bio  compensation   reuters w james oshea director age  bio  compensation   reuters jeffrey s heier md independent director age  bio  compensation   reuters full list on reuters » google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service ocular therapeutix inc private company information  bloomberg july    am et pharmaceuticals company overview of ocular therapeutix inc snapshot people company overview ocular therapeutix inc a biopharmaceutical company focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the united states it markets resure sealant a hydrogelbased ophthalmic wound sealant to seal corneal incisions following cataract surgery the company’s lead product includes dextenza which is in phase iii clinical trial for the treatment of postsurgical pain and inflammation allergic conjunctivitis and in phase ii clinical trial for the treatment of inflammatory dry eye disease it is also developing otxtp which is in phase iii clinical trial for glaucoma and ocular hypertens ocular therapeutix inc a biopharmaceutical company focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the united states it markets resure sealant a hydrogelbased ophthalmic wound sealant to seal corneal incisions following cataract surgery the company’s lead product includes dextenza which is in phase iii clinical trial for the treatment of postsurgical pain and inflammation allergic conjunctivitis and in phase ii clinical trial for the treatment of inflammatory dry eye disease it is also developing otxtp which is in phase iii clinical trial for glaucoma and ocular hypertension in addition the company has preclinical development of intravitreal depot with proteinbased or small molecule drugs including tyrosine kinase inhibitors for the treatment of wet agerelated macular degeneration and other retinal diseases it has a strategic collaboration option and license agreement with regeneron pharmaceuticals inc for the development of sustained release formulation of the vascular endothelial growth factor trap aflibercept for the treatment of wet agerelated macular degeneration and other serious retinal diseases ocular therapeutix inc was founded in  and is headquartered in bedford massachusetts detailed description  crosby drivesuite bedford ma united statesfounded in  employees phone  fax  wwwocutxcom key executives for ocular therapeutix inc dr amarpreet sawhney phd founder chairman chief executive officer and president age  total annual compensation k mr james fortune chief operating officer age  total annual compensation k compensation as of fiscal year  ocular therapeutix inc key developments rosen law firm expands first filed securities class action against ocular therapeutix inc to include investors who purchased up to july   jul   rosen law firm announced that it has filed a class action lawsuit on behalf of purchasers of ocular therapeutix inc securities from may   through july   inclusive class period the lawsuit seeks to recover damages for ocular investors under the federal securities laws according to the lawsuit throughout the class period defendants made false andor misleading statements andor failed to disclose that ocular’s management has been misleading investors about dextenza manufacturing issues including that more than  of lots manufactured by ocular contain bad product such manufacturing issues could imperil the approval of dextenza by the fda and as a result defendants’ public statements were materially false and misleading at all relevant times on july   seeking alpha published an article concerning dextenza manufacturing issues on that same day stat published an article asserting that dextenza could be rejected by the fda because of product contamination on this news shares of ocular therapeutix fell  per share or over  over two trading days to close at  per share on july   damaging investors on july   ocular disclosed that it received a complete response letter from the fda stating “that the fda has determined that it cannot approve the nda in its present form” on this news shares of ocular fell  per share or over  to close at  per share on july   further damaging investors ocular therapeutix inc  special call jul   to provide details on amendment to potentially extend review for dextenza™ new drug application rosen law firm files class action lawsuit on ocular therapeutix inc jul   rosen law firm announced that it has filed a class action lawsuit on behalf of purchasers of the securities of ocular therapeutix inc from may   through july   both dates inclusive the lawsuit seeks to recover damages for ocular therapeutix investors under the federal securities laws according to the lawsuit defendants throughout the class period made false andor misleading statements andor failed to disclose that  ocular therapeutix’s management has been misleading investors about dextenza manufacturing issues including that more than  of lots manufactured by ocular therapeutix contain bad product  such manufacturing issues could imperil the approval of dextenza by the fda and  as a result defendants’ public statements were materially false and misleading at all relevant times when the true details entered the market the lawsuit claims that investors suffered damages similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact ocular therapeutix inc please visit wwwocutxcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close ocular therapeutix inc ocular therapeutix inc ocular therapeutix is a biopharmaceutical company dedicated to the discovery development manufacturing and commercialization of innovative drug products focused on the treatment of ocular diseases and conditions new slide text – ocular therapeutix feature products intracanalicular inserts extended release dexamethasone and extended release travoprost caution new drugs  extended release intracanalicular inserts are investigational new drugs undergoing clinical evaluation in the us and are not approved by the fda as safe or effective read more about intracanalicular inserts sustained release intravitreal depots evaluating small tki and large protein molecule drug depots for retinal diseases caution new drugs – sustained release intravitreal depots are investigational new drugs in preclinical development that are not approved by the fda as safe or effective read more about sustained release intravitreal depots ocular sealant resure sealant caution new drugs  extended release intracanalicular inserts are investigational new drugs undergoing clinical evaluation in the us and are not approved by the fda as safe or effective read more about the resure sealant top ocular therapeutix  office foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingplanning a trip to bostonfoursquare can help you find the best places to go tofind great things to doocular therapeutixofficebedfordsavesharetipsocular therapeutixno tips and reviewslog in to leave a tip herepostno tips yetwrite a short note about what you liked what to order or other helpful advice for visitors photorelated searchesocular therapeutix bedford  ocular therapeutix bedford photos  ocular therapeutix bedford location  ocular therapeutix bedford address  ocular therapeutix bedford  ocular therapeutix bedford  aboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano 語 한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeymore great places in bedfordabcdefghijklmnopqrstuvwxyzfoursquare    lovingly made in nyc  sfocular therapeutix crosby drbedford ma united statesget directions ocutxcomsee moreunited states » massachusetts » middlesex county » bedfordis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around you bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one